DBV Technologies Files 2025 Annual Report and Registration Document

DBV Technologies, a late-stage biopharmaceutical company, has announced the filing of its 2025 Annual Report on Form 10-K with the U.S. Securities and Exchange Commission (SEC) and its Universal Registration Document with France's Autorité des Marchés Financiers (AMF). These filings cover financial activities up to December 31, 2025.

In accordance with French legislation, the Universal Registration Document includes several key reports. Among them are the 2025 financial report, corporate governance details, a description of the share buy-back program, and statutory auditor reports, including auditor fees. Interested parties can access these documents on DBV Technologies' website, while the Form 10-K and 2025 URD are available on the SEC and AMF websites respectively.